Biomedical Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +44 2038689735

- Biomedical Research (2010) Volume 21, Issue 1

Effects of Recombinant Human Erythropoietin (rHuEPO) Treatment on Plasma Insulin-like Growth Factor-I (IGF-I) and Hemoglobin Concentra-tions in Patients with Type 2 Diabetes Mellitus Associated with Neph-ropathy and Anemia of Chronic Renal Failure.

Both insulin-like growth factor-I (IGF-I) and erythropoietin (EPO) have been found to stimulate erythropoiesis, and IGF-I levels are decreased in patients with chronic renal fail-ure (CRF). Decreased IGF-I levels might contribute to the progression of anemia of CRF. However, no studies have examined the effects of rHuEPO therapy on plasma IGF-I levels and Hb concentration in predialysis diabetic patients with CRF and anemia. Therefore, we investigated the effects of rHuEPO treatment on plasma IGF-I levels and Hb concentrations in patients with diabetes and anemia of CRF. Seven patients with type 2 diabetes mellitus accompanied by advanced nephropathy (renal failure stage) were studied. The mean (±SE) age was 62.6±6.2yrs. Serum creatinine and creatinine clearance levels were 327.1±44.2 μmol/L and 0.261±0.022 ml/s, respectively. Re-combinant human EPO (rHuEPO) was subcutaneously infused into the abdomen for 4 weeks at a flow rate of 6,000 IU/2.5ml/week using a portable infusion pump. Plasma EPO levels were increased from 19.4±2.2 IU/L to 69.6±16.9 IU/L 1 week after the start of rHuEPO administration, and were maintained at a steady state. Plasma IGF-I lev-els at time 0 decreased to 72.7±8.4 μg/L compared with age-matched diabetic patients with-out nephropathy (166.0±15.5 μg/L). Plasma IGF-I levels were increased 1-3 weeks after the start of rHuEPO administration, followed by an increase in Hb concentrations 3-4 weeks after rHuEPO administration. We have therefore hypothesized that rHuEPO administration increases plasma IGF-I levels followed by Hb concentrations. These findings suggest that rHuEPO treatment has a stimulatory effect on IGF-I production, and that increases in IGF-I might be a good indica-tor of improved Hb concentrations.

Author(s): Motoi Sohmiya and Yoko Sohmiya

Abstract Full Text PDF

Get the App